Evidence map›Paper›PMID 35258413›Full record

ArticleCell cycle (Georgetown, Tex.)2022

Hsa-miR-186-3p suppresses colon cancer progression by inhibiting KRT18/MAPK signaling pathway.

Tian Xia, Zhiyong Zhang, Xin Zhang, Quanfu Li

RetractedOpen access · bronzeAbstract readRetracted Publication
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Tian XiaDepartment of Anorectal Surgery, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430000, Hubei, China.
Zhiyong ZhangDepartment of Colorectal Anal Surgery, Zhengzhou University First Affiliated Hospital, Zhengzhou 450000, Henan, China.ORCID 0000-0002-3175-2737
Xin ZhangDepartment of Colorectal Anal Surgery, Zhengzhou University First Affiliated Hospital, Zhengzhou 450000, Henan, China.
Quanfu LiDepartment of General Surgery, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430000, Hubei, China.
First Affiliated Hospital of Zhengzhou University · CNTongren Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to determine the effect of miR-186-3p and KRT18 interaction on the biological behavior of colon cancer cells. A biotin-microRNA pull-down assay was performed to identify potential miRNAs. qRT-PCR was used to verify the KRT18 and miR-186-3p levels. In addition, Western blotting was used to detect the KRT18 protein levels. The functional connection between KRT18 and miR-186-3p was confirmed using a dual luciferase reporter assay. BrdU incorporation, MTT assay, and flow cytometry were performed to verify the biological function coupled with in vivo assays. A significant decrease in miR-186-3p expression was observed in colon carcinoma tissues and cells. Functionally, overexpression of miR-186-3p displayed an obvious suppressive action on cell proliferation and viability, and a stimulatory action on the apoptotic ability of SW620 and SW480 cells. Conversely, reduced miR-186-3p had a marked stimulatory effect on proliferation and viability, and a suppressive apoptotic effect. Inhibition of tumorigenesis was observed in mice treated with the miR-186-3p agomir. Furthermore, we identified that miR-186-3p regulated KRT18 levels in colon carcinoma, where silenced KRT18 suppressed proliferation and viability and promoted apoptosis. However, the addition of a miR-186-3p inhibitor weakened the effects of si-KRT18. Additionally, the activation of MAPK signaling pathway upon miR-186-3p silencing was antagonized by the combined transfection of si-KRT18 and miR-186-3p inhibitor. miR-186-3p suppresses proliferation and viability, but facilitates apoptosis in colon cancer cells by targeting KRT18 and negatively regulating the MAPK signaling pathway, indicating that the miR-186-3p/KRT18 axis may be a promising therapeutic target for colon carcinoma.

Indexed as

Colonic NeoplasmsMicroRNAsAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceSignal TransductionMicroRNAsMIRN186 microRNA, humanapoptosiscolon cancerKRT18miR-186-3pproliferationviability

Identifiers

PMID35258413
PMCPMC8973355
OpenAlexW4220810379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.